Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Clinical trial NCT04892264 · TERMINATED

Trial details

NCT number: NCT04892264
Sponsor: Mayo Clinic
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Plasma Cell Myeloma Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma

Start date: 2021-06-03
Primary completion: 2024-03-18
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.